Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK211 in Advanced Solid Tumors With KRAS Alteration
NCT07718165Phase 1Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABSK211 in solid tumor, sponsored by Abbisko Therapeutics. Primary endpoints: Dose-Limiting Toxicities, Adverse Events and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
ABSK211
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07718165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07718165.